In a patient with Enterococcus faecalis bacteremia, acute kidney injury, and penicillin and sulfonamide allergy, who has a daptomycin‑susceptible isolate, which antibiotic—daptomycin or vancomycin—is less nephrotoxic?

Daptomycin is Less Nephrotoxic Than Vancomycin for Daptomycin-Susceptible E. faecalis Bacteremia

In a patient with Enterococcus faecalis bacteremia, acute kidney injury, and penicillin/sulfonamide allergy who has a daptomycin-susceptible isolate, daptomycin is the preferred agent over vancomycin due to significantly lower nephrotoxicity risk.

Nephrotoxicity Comparison

The evidence consistently demonstrates that daptomycin causes substantially less kidney injury than vancomycin in clinical practice:

• A multicenter Spanish study found nephrotoxicity occurred in only 6.3% of daptomycin-treated patients versus 23.3% of vancomycin-treated patients (p=0.006), despite the daptomycin group having worse baseline renal function 1

• Another comparative study showed acute kidney injury rates of 9% with daptomycin versus 23% with vancomycin (p=0.043) 2

• The FDA label for vancomycin explicitly warns that systemic exposure may result in acute kidney injury (AKI), with risk increasing as serum levels increase, particularly with concomitant nephrotoxic drugs or pre-existing renal impairment 3

• Daptomycin's FDA label does not list nephrotoxicity as a primary adverse effect 4

Critical Context for Your Patient

Your patient has existing acute kidney injury, which creates two compounding problems with vancomycin:

1. Higher baseline risk: Pre-existing renal impairment is an established risk factor for vancomycin-induced nephrotoxicity 3

2. Therapeutic monitoring challenges: Achieving target vancomycin trough levels of 15-20 mg/L (recommended for serious infections 5) becomes more difficult and dangerous in AKI, as the drug accumulates

Dosing Recommendations

For E. faecalis bacteremia with daptomycin susceptibility:

• Daptomycin 8-10 mg/kg IV once daily for standard bacteremia 6
• Consider 10-12 mg/kg/day for endocarditis or if MIC approaches the susceptible breakpoint 7
• Monitor CPK levels weekly for myopathy 8

Important Caveats

Daptomycin is not FDA-approved for enterococcal infections 7, though it has Class IIb recommendation from AHA guidelines for multidrug-resistant enterococcal endocarditis 7. However, given your patient's penicillin allergy, AKI, and daptomycin susceptibility, this represents the safest available option.

Monitor for daptomycin-specific toxicities: While nephrotoxicity is rare, daptomycin can cause myopathy and elevated CPK. Check CPK at baseline and weekly 8. Some experts recommend adding a beta-lactam (if tolerated after allergy evaluation) or fosfomycin to prevent resistance emergence 8.

Verify the penicillin allergy: If the allergy is non-anaphylactic, ampicillin remains the optimal choice for E. faecalis as it is bactericidal and has superior outcomes 8. Consider infectious disease consultation for possible penicillin desensitization 8.